Financial Performance - Operating revenue for the first nine months of 2023 was CNY 146,079,179.30, a decrease of 5.83% from CNY 155,119,768.26 in the same period of 2022[11]. - Net profit attributable to shareholders decreased by 42.56% to CNY 18,825,425.25 from CNY 32,774,990.97 year-on-year[11]. - Basic earnings per share dropped by 55.98% to CNY 0.27 from CNY 0.62 in the previous year[11]. - The company's net profit for the reporting period was CNY 18.68 million, a decrease of 43.01% year-on-year, mainly due to a decline in operating profit[15]. - Operating profit for the period was CNY 20.45 million, down 45.39% year-on-year, influenced by weaker pricing power in the pharmaceutical packaging equipment sector[14]. - The total comprehensive income for Q3 2023 was CNY 18,676,879.59, compared to CNY 32,774,990.97 in Q3 2022, reflecting a decline of about 43%[51]. Cash Flow - Cash flow from operating activities turned negative at CNY -889,402.76, a decline of 102.12% compared to CNY 42,009,832.91 in the same period last year[11]. - The cash inflow from operating activities for the first nine months of 2023 was CNY 132,667,232.20, compared to CNY 156,638,615.22 in the same period of 2022, a decrease of approximately 15.3%[52]. - The net cash outflow from operating activities for the first nine months of 2023 included CNY 66,947,274.93 for purchasing goods and services, compared to CNY 56,659,309.75 in the same period of 2022, an increase of approximately 18.5%[52]. - The net cash flow from operating activities for Q3 2023 was 4,738,607.04 CNY, a decrease of 76.1% compared to 19,637,657.33 CNY in Q3 2022[56]. - The company reported a total cash outflow of 131,597,623.05 CNY from operating activities, an increase of 25.3% from 105,194,430.01 CNY in Q3 2022[56]. Assets and Liabilities - Total assets increased by 6.15% to CNY 460,684,867.24 as of September 30, 2023, compared to CNY 433,992,572.72 at the end of 2022[11]. - The company's cash and cash equivalents decreased by 30.57% to CNY 123,868,801.30, primarily due to investments in a subsidiary's automation equipment production base[12]. - The total number of shares outstanding is 68,500,000, with 37.80% being unrestricted shares and 62.20% being restricted shares[19]. - The company has a total of CNY 61,088,749.02 in assets that are either pledged or restricted, accounting for about 13.26% of total assets[32]. - The company reported a total liability of CNY 89,533,145.22 in current liabilities, which is slightly up from CNY 86,938,588.19, showing an increase of about 2%[38]. Investments and Expenses - Cash outflow for purchasing fixed assets and other long-term assets was 94,807,571.17 CNY, compared to 1,622,268.50 CNY in the previous year, indicating a significant increase in capital expenditures[56]. - Research and development expenses for Q3 2023 were CNY 7,618,542.06, slightly down from CNY 7,635,919.21 in Q3 2022, indicating a marginal decrease[50]. - Total operating costs increased to CNY 131,989,352.59, up 15.5% from CNY 114,269,255.75 year-on-year[46]. Shareholder Information - The largest shareholder, Bi Chunguang, holds 26.72% of the shares, amounting to 18,301,266 shares[22]. - The total number of shareholders holding more than 5% of shares or among the top ten shareholders is 47,574,162, representing 69.47% of the total shares[22]. - There are no pledged or judicially frozen shares among the top ten shareholders[23]. Financial Management - The company's financial expenses decreased by 49.63% year-on-year to CNY 1.04 million, due to effective cost management[13]. - The company's credit impairment losses decreased by 48.52% year-on-year to CNY 3.20 million, reflecting improved collection of receivables[14]. - The cash flow from financing activities increased by 197.11% year-on-year to CNY 17.71 million, driven by increased short-term and long-term borrowings[15].
春光药装(838810) - 2023 Q3 - 季度财报